Observational study to examine the burden of chronic anemia in myelodysplastic syndromes and beta-thalassemia
SUMMIT, N.J. & SEATTLE–(BUSINESS WIRE)–Celgene Corporation (NASDAQ: CELG) and Sage Bionetworks today announced a collaboration to develop an iPhone application utilizing the Apple ResearchKit framework to improve the understanding of the burden of disease for patients living with chronic anemia due to myelodysplastic syndromes (MDS) or beta-thalassemia.
Smartphone-based apps like Sage Bionetworks’ mPower for Parkinson’s disease are increasingly being utilized as a tool by clinical study researchers to collect and analyze increasing volumes of patient-reported data in order to better capture and understand disease burden better and to improve therapeutic developments. Smartphone clinical study apps also enable the return communication of important study information to the patient participants.